<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02280135</url>
  </required_header>
  <id_info>
    <org_study_id>TC/RP</org_study_id>
    <secondary_id>2012-000618-12</secondary_id>
    <nct_id>NCT02280135</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Intravitreal Injection of Autologous Bone Marrow Stem Cells in Patients With Retinitis Pigmentosa</brief_title>
  <acronym>TC/RP</acronym>
  <official_title>Phase I Clinical Trial of Intravitreal Injection of Autologous Bone Marrow Stem Cells in Patients With Retinitis Pigmentosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Red de Terapia Celular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Spanish National Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Virgen de la Arrixaca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Public Health Service, Murcia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto Murciano de Investigación Biosanitaria Virgen de la Arrixaca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Red de Terapia Celular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of intravitreal injection of autologous
      bone marrow stem cells in patients with retinitis pigmentosa by a prospective, single-center,
      randomized, parallel, double-blind, phase I placebo-controlled clinical trial.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of serious and non-serious adverse events related with the use of bone marrow mononuclear cells in patients with retinitis pigmentosa</measure>
    <time_frame>12 months from baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life: Questionnaire VFQ-25 (Visual Function Questionnaire-25).</measure>
    <time_frame>12 months from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity (VA): Test ETDRS (Early Treatment Diabetic Retinopathy Study).</measure>
    <time_frame>12 months from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Color Vision: Ishihara Color Test.</measure>
    <time_frame>12 months from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast sensitivity: CSV-1000E.</measure>
    <time_frame>12 months from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraocular pressure (IOP): measured in mm Hg with applanation tonometer Haag Streit AT 900.</measure>
    <time_frame>12 months from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Examination of the anterior and posterior pole: Made with biomicroscopy (BMC).</measure>
    <time_frame>12 months from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Width of retinal macula layer and nerve fiber: Measured with Optical Coherence Tomography Spectral domain (OCT)(Topcon 3D OCT-2000 Spectral Domain OCT).</measure>
    <time_frame>12 months from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual field (VF) and macular sensitivity (The Humphrey perimeter).</measure>
    <time_frame>12 months from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study eye fundus: Made by Retinography and Angiography fluorescein.</measure>
    <time_frame>12 months from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrical retinal function: electroretinogram (ERG) (altered / unaltered).</measure>
    <time_frame>12 months from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual evoked potentials with Pattern Reversal (VEP) (altered / no altered).</measure>
    <time_frame>12 months from baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Retinitis Pigmentosa</condition>
  <arm_group>
    <arm_group_label>Intravitreal injection of Autologous bone marrow Stem Cell</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients included in the trial will receive a pars plana intravitreal injection of autologous mononuclear cells (MNC) of bone marrow (BM) in one eye (experimental group A or group). The eye in which autologous BM MNCs were injected will be determined randomly.
The average dose will be 30 million of cells (5-60 million) diluted in 0.1 ml. of saline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subconjunctival injection of saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients included in the trial will receive a subconjunctival injection of 0.1 ml of saline (SF) (placebo) in the fellow eye (group B or control group). In this way the patient will receive an injection in the control eye but avoid the risks of intraocular injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intravitreal injection of Autologous bone marrow Stem Cell</intervention_name>
    <description>We will proceed to the injection of 0.1 ml of the suspension with the autologous MNC of BM avoiding coincide with conjunctival and scleral hole and perpendicular to the sclera.
After the injection, a dry, sterile dressing will be placed to prevent reflux. Immediately, the perception of light, the movement of the central retinal artery, the venous pulse and the color of the papilla will be evaluated. If necessary, anterior chamber paracentesis will be performed.
After injection, the patient will remain with closed eyes and sitting, waiting for cells will be deposited on the bottom of the eyeball and for 3 days will instill tropicamide collyrium every 12 hours.</description>
    <arm_group_label>Intravitreal injection of Autologous bone marrow Stem Cell</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Subconjunctival injection of saline</intervention_name>
    <description>In the control eye, will make a subconjunctival injection of 0.1 ml saline. To realize contralateral injection gloves and all surgical materials will change, trying extreme measures of sterility.
After injection, the patient will remain with closed eyes and sitting, waiting for cells will be deposited on the bottom of the eyeball and for 3 days will instill tropicamide collyrium every 12 hours.</description>
    <arm_group_label>Subconjunctival injection of saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Retinitis Pigmentosa bilateral diagnosis.

          -  Visual acuity (measured with ETDRS) less than or equal to 20/70 and visual field below
             30° central in both eyes.

          -  Signed informed consent

          -  Warranty sufficient adherence to protocol. It must fulfill all inclusion criteria.

        Exclusion Criteria:

          -  Concurrence of any systemic or ocular disease that precludes or affects tracking study
             variables. Specifically retinal involvement with diabetes mellitus, glaucoma, macular
             degeneration or age.

          -  Eye surgery in the previous 6 months.

          -  Patients who are pregnant.

          -  Patients with active lactation.

          -  Physically fertile patients, defined as all women physiologically capable of becoming
             pregnant, including women whose career, lifestyle or sexual orientation excludes
             sexual intercourse with a man and women whose partners have been sterilized by
             vasectomy or other methods, UNLESS tHEY are using a reliable contraceptive method.
             This birth control method can be:

          -  Complete abstinence from sexual intercourse

          -  Surgical sterilization (tubal ligation)

          -  Surgical sterilization partner (vasectomy)

          -  Implanted or injectable hormonal contraceptives and oral.

          -  Patients with cardiac disease, renal, hepatic, systemic, immune that might influence
             the survival of patients during the test.

          -  Positive serology for hepatitis B, hepatitis C or HIV.

          -  Clinical criteria or anesthetics that contraindicate the sedation or the extraction of
             BM (Altered coagulation system or anticoagulated patient with inability to withdraw
             anticoagulation, hemodynamic instability, altered skin in the puncture site, etc.)

          -  Participation in other clinical trials.

          -  Inability to sign informed consent or understanding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>María Elena Rodriguez González-Herrero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Virgen de la Arrixaca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Universitary Hospital Virgen de la Arrixaca</name>
      <address>
        <city>El Palmar</city>
        <state>Murcia</state>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2014</study_first_submitted>
  <study_first_submitted_qc>October 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2014</study_first_posted>
  <last_update_submitted>March 29, 2017</last_update_submitted>
  <last_update_submitted_qc>March 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
    <mesh_term>Cone-Rod Dystrophies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

